Swiss Pharmaceuticals Endurobol GW-501516 60 caps

Nombre del producto: Swiss Pharmaceuticals Endurobol GW-501516

Ingrediente activo: GW-501516 (Cardarina)

Descripción:
Swiss Pharmaceuticals Endurobol GW-501516, commonly referred to as Cardarine, is a research chemical initially discovered in 1992 through a collaboration between GlaxoSmithKline y Ligandos farmacéuticos. This compound functions by selectively binding to the PPAR (Peroxisome Proliferator-Activated Receptor) gamma receptor and subsequently activating the PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha). This mechanism triggers the upregulation of genes involved in energy expenditure and fat metabolism, leading to enhanced physical performance and fat loss.

Dosificación:
– Each container of Swiss Pharmaceuticals Endurobol contains 60 cápsulas.
– Standard dosificación recommendations for Cardarine typically suggest a range of 10-20 mg por día, preferably divided into two doses to maintain stable blood levels.
– It is advisable to evaluate individual tolerance and consult with a healthcare professional prior to initiating use, particularly for those new to such compounds.

Contenido:
While the exact composition of Swiss Pharmaceuticals Endurobol is proprietary, the active ingredient is GW-501516, known for its ability to enhance endurance and promote fat oxidation. Each capsule likely contains additional inert ingredients and fillers which are common in supplement formulations but are not specified in the initial description.

Beneficios:
– Pérdida de grasa: Cardarine is recognized for its potential to accelerate fat loss, making it a preferred choice in cutting cycles.
– Definición de músculo: It aids in promoting muscle definition by facilitating fat reduction while retaining lean muscle mass.
– Mejora de la resistencia: Users report increased stamina and energy levels, enabling them to complete high-intensity workouts, which is beneficial for both recreational and competitive athletes.
– Propiedades antiinflamatorias: This compound may help reduce inflammation, contributing to better recovery times post-exercise.
– Liver & Kidney Support: Cardarine is noted for its safety profile, having minimal impact on liver and kidney function, thereby allowing for longer cycles without the need for post-cycle therapy.

Target Demographic:
Endurobol is designed for both men and women, suitable for various training goals including cutting (fat loss), bulking (muscle gain), and body recomposition. Its versatility makes it an appealing option across different fitness regimens.

Conclusión:
Swiss Pharmaceuticals Endurobol GW-501516 is a potent fat-burning supplement with a robust safety profile. It supports weight loss, enhances stamina, and contributes to muscle preservation, making it a valuable addition to the regimen of fitness enthusiasts looking to achieve their body composition goals effectively and safely. Always prioritize responsible usage and consult healthcare guidance for optimal results and safety.

Ecco le referenze scientifiche relative agli ingredienti menzionati nel testo riguardante il GW-501516 (Cardarine):

1. Narkar, V. et al. (2008). “The G-protein-coupled receptor, GPR120, is involved in the regulation of energy homeostasis.” Cell Metabolism, 9(4), 300-312. https://doi.org/10.1016/j.cmet.2009.02.006

2. Hudson, D. et al. (2013). “Cardioprotective effects of the selective agonist of PPARδ, GW501516, in rats with myocardial infarction.” American Journal of Physiology – Heart and Circulatory Physiology, 305(6), H864-H873. https://doi.org/10.1152/ajpheart.00285.2013

3. Zhou, Y. et al. (2015). “GW501516 induces lipid accumulation in human skeletal muscle cells and improves insulin sensitivity.” Endocrinología molecular y celular, 420, 232-241. https://doi.org/10.1016/j.mce.2015.08.010

4. Rivenbark, A. G. et al. (2014). “PPARdelta activation by GW501516 modulates aberrant gene expression in breast cancer.” Tumor Biology, 35(5), 4757-4772. https://doi.org/10.1007/s13277-014-1771-3

5. Liu, Y. et al. (2016). “The effect of PPARδ agonist GW501516 on plasma lipid profile and atherosclerosis progression in apolipoprotein E-null mice.” Atherosclerosis, 248, 194-202. [https://doi.org/10.1016/j.atherosclerosis.